86 9 Heilongjiang Jilin Beijing (1)(2) 200827,440.82009 31,228.2201037,381.6
2008697.020091,296.82010 1,368.320092009 536.42010 8,075.229,149.91,725.5 21.6%78.0%4.6% 2009 70.0% 2009 78.5% 79.1%201012 31400 201012315322010 52.4%6 cgmp 87
200920101231 4132 2009 67.0% 200939.1%2009 11.0%20114 CHS2009 201058.8% 7,60022963.8% 87955.7%2010 61.9% 920101231 1,6821,187363 4952009 10,000 88
201013.2% 200920058,660 17,205201432,651 2009201422.4% 23.4% 2009 2009 39.1% CHS 89
201012 31532 201052.4% IIA 6 cgmp 2005Hoffmann-La Roche Ltd. 90
200454438 201012313327 6 55020.0% 20 2008200920104.126.8 76.12010123134.5 201012314132 2009 67.0%CHS 201058.8% 7,600 22963.8%87955.7% 201061.9% 91
201012313320095092 100 201013.2% 92
1982 20114Pfizer, Inc. 33 158 20 20101231532 93
6 2010 94
5 2009 95
20094 96
97
9 1231 2008 2009 2010.............. 6,014,432 832,288 6,846,720 6,369,666 952,961 7,322,627 7,011,995 1,063,169 8,075,164...... 19,683,695 530,522 20,214,217 23,117,630 650,884 23,768,514 28,348,117 801,810 29,149,927.............. 1,413,818 1,413,818 1,521,524 1,521,524 1,725,546 1,725,546.......... 328,816 67,979 396,795 219,343 62,017 281,360 295,910 38,975 334,885............... 27,440,761 1,430,789 31,228,163 1,665,862 37,381,568 1,903,954 2009 70.0%201020.0%20082009 20106,014.46,369.7 7,012.06,846.77,322.68,075.2 20101231950492313 24601505215 IIA 98
20101231 20101231 2010123133 276 2010123149231324 56 2010123153 2200820092010 46.5%49.7%52.4% 6 99
1231 2008 2009 2010............. 2,089.6 30.5% 2,422.0 33.1% 2,740.9 33.9%............. 2,513.4 36.7 2,621.3 35.8 2,664.4 33.0............. 626.4 9.2 819.0 11.2 1,076.9 13.3............. 673.2 9.8 560.8 7.7 683.1 8.5................ 5,902.6 86.2 6,423.1 87.8 7,165.3 88.7 (1)........... 944.1 13.8 899.5 12.2 909.9 11.3................ 6,846.7 100.0% 7,322.6 100.0% 8,075.2 100.0% (1) 20082009 20102,089.62,422.02,740.9 30.5%33.1%33.9%20101231 (1) IIA (1) (2) 100
20275 (3) 20124 202410 (3) 20142 20162 (1)(2) (1)(2) (2) (2) (2) (1) 20233 A (1) 2010100.0 (2) (3) 101
2008200920102,513.4 2,621.32,664.436.7%35.8% 33.0%2010123118 8 1152010 1231 (1) 20256 20159 (1) (1) 202711 (1) (1) 202612 (1) 20269 20258 20145 20143 (1) (1) 20134 (1) (1) 20198 20206 (1) 2010100.0 102
200820092010 626.4819.01,076.9 9.2%11.2%13.3%20101231 2420101231 (1) (2) (1) Urinary Kallidinogenase for Injection (2) 20235 20181 202411 (1) (1) 2010100.0 (2) 201111 200820092010 673.2560.8683.1 9.8%7.7%8.5% 103
2010123120524118 531045 23171123 20101231319 200454438 82008 35 20082009 20104.126.876.1 2010123134.5 200820092010228.8259.2 285.7 (i)(ii) (iii) 213 2010123155020.0% 2010123140 10 104
3 2010 2004 201124 20101231 105
201012313327 6 Etanercept Etanercept EtanerceptEtanercept Etanercept Etanercept 50%Etanercept LT LT LTLT50% LT2020 50% LVCR LVCR LVCRLVCR50%LVCR 106
2023 2016 BB 2024 2018 Bekhterev 20132014 2013 107
201012 312,220,000770,000 20101231 6 1231 2008 2009 2010 (1) (2) (1) (2) (1) (2).......... 41.0 76.8% 41.0 70.6% 41.0 70.0%.......... 3.6 63.8 3.6 64.8 3.6 65.5........ 1.7 90.2 1.7 100.4 1.7 100.3........ 1.1 59.7 1.1 67.4 1.1 67.5........ 2,800.0 50.7% 2,800.0 49.5% 2,860.0 49.5% (1) (2) 200820092010 131,700 2010123122,000 108
117,000 51,000 1,581,500 20101231 13 1 109
110
1231 2008 2009 2010.............................. 3,555 3,623 3,550......................... 769 1,053 1,025..................... 701 1,126 1,221............... 68 (73) (196).............................. 3,623 3,550 3,354 20082009 2010 3012020082009 2010 200820092010 12.2%13.0%13.2% 111
200820092010 20107900 222010 10.8%2011335 2200820092010 2.1%2.4%2.6% 20113200811 200820092010 109.4110.5104.9 200820092010 112
20082009 201023.9% 14.5%13.0% 18.4 60.0%10.0%30.0%1982 5030.0% 30.0% 30 TM 2008 2009201077.6105.2 89.6 Roche (China) Holding Co., Ltd. 62.4Roche (China) Holding Co., Ltd. 21.9%48.1%30.0%1994 5030.0% 30.0% CellCept 200820092010 96.9101.7120.4 113
1993 100.0200451.0%2009 640.8%20101231Nycomed S.C.A. SICAR51.3% 20096 200820092010 201111 20101231532 200820092010 211.5352.3491.5352.2 480.0632.0267.6 367.2512.0 200920101231 4132 2009 67.0% 200939.1%2009 11.0% 200820092010 19,683.723,117.628,348.1 20,214.223,768.529,149.9 18,600 2010 61.9%2010123141 327,600 22963.8%87955.7% 20114 114
CHS2009 1231 2008 2009 2010........... 12,366.4 62.8% 14,778.9 63.9% 17,553.6 61.9%........... 7,317.3 37.2 8,338.7 36.1 10,794.5 38.1.............. 19,683.7 100.0% 23,117.6 100.0% 28,348.1 100.0%......... 530.5 2.7 650.9 2.8 801.8 2.8....... 20,214.2 102.7% 23,768.5 102.8% 29,149.9 102.8% 201012317,60012 4132 115
20107 49.0%20108 51.0%201011 CHS 1231 2008 2009 2010............. 18,277.3 92.9% 21,481.7 92.9% 25,058.8 88.4%............. 268.7 1.4 330.0 1.4 467.0 1.6............. 136.4 0.7 210.1 0.9 884.8 3.1............. 1,001.3 5.1 1,095.8 4.7 1,937.5 6.8....... 19,683.7 100.0% 23,117.6 100.0% 28,348.1 100.0% 201012317,6002,3002,200 116
(i) (ii) (iii)(iv) (v) 200820092010 200820092010 117
12,366.414,778.917,553.6 62.8%63.9%61.9% 200820092010 12311,8002,3502,300 200820092010 7,317.38,338.710,794.5 37.2%36.1%38.1% 20092 20092010 118
21.8201.7 30120 60 20082009 2010 2,6003350 92100 6688 200820092010 119
2010123118,600 2,600 20101231 2,600 2,000-3 D -2b AD (18AA) 120
1,200 1,100 1,000 700 700 570 470 470 A 450 70 121
260 120 30 80 3,000 180 122
20101231 2,600 100 80 790 (i)(ii) (iii)(iv) (v)(vi)24 (i) (ii) (iii) 6122 123
2009H1N14254 170,000H1N1200820092010 20114 5,00020,000 200820092010 41.938.440.8 2009 200820092010 1,413.81,521.51,725.5 124
920101231 1,6821,187363 4952009 20101231.................................... 436 323 759 (1)................................... 363 363.................................... 60 15 75.................................... 86 0 86.................................... 78 9 87.................................... 42 4 46................................... 60 144 204.................................... 40 0 40.................................... 22 0 22.................................... 1,187 495 1,682 (1) 201012311,1879 200820092010 1,413.81,521.51,725.5 20101231495 20101231 125
10,000 2322 6236 152 126
CHS 201143,569.0CHSCHS 2009 2009 18201012315,000 4001032010 51% 200820092010CHS3,214.44,343.4 6,111.971.493.6 131.7 2010121,487.8 96.9%100%2011 5359 20101231 66(Benazepril Hydrochloride) 127
2010491.9 2008200920101,657.71,621.9 1,414.1112.9 108.788.4 20114 Prevenar (7-valent) 6 2008200920105.6%5.9% 5.1%1.4%1.4%1.2% 5% 2008200920101231 5,152.95,756.27,739.7 2008200920101231 566.4608.0613.5 2008200920107.7%8.4% 128
9.1%2.5%2.6%2.6% 5% 201012 31319 20101231218 20095 201010 2006 201011 2008200920105.0 3.03.9 20101231806 10 129
20095,300 2009201012 31950 130
2009123110,0002009 320.9% 20094.6% 2009 2009387,870 131
200820092010 132
(i)(ii) 200820092010 (i) 133
(ii)(iii) 200820092010 134
ISOISO14001 200820092010 30.26.98.2 200811 (i) (ii) (iii)(iv) (v) 200 135
20112281,3861,389,383 652,322 228,128243,347 265,587 1,0761,076,079 3644,040 344333,505 185167,193 201212 6362,873 253287,8972011228 20.7% 25311 136
101 141 253 10% 5725,4062011228 1.8% 310 20 5,265 20112281647,348 16,77212 10% 2011228815445,692 373,889446 71,802369 369 137
7,9576 20112283,381.7 2,433.1 200820092010123131,85630,19031,493 20101231.................................................. 11,524 36.6%......................................... 12,315 39.1................................ 3,055 9.7....................................... 3,062 9.7 (1)................................................ 1,537 4.9................................................ 31,493 100.0% (1) 2008200920101,521.31,569.5 1,628.3 138
5 20086200580.0 2009 200920111 2011331 2011331 72.6 139
140